TY  - JOUR
T1  - Cell-Free Pharmaceutical Biotechnology as a Modular Manufacturing Architecture for Rapid, Distributed, and Reconfigurable Therapeutic Production across Therapeutic Modalities
A1  - Hassan Ali
A1  - Mariam Farooq
A1  - Usman Shah
A1  - Bilal Khan
A1  - Sana Malik
JF  - International Journal of Pharmaceutical Research and Allied Sciences
JO  - Int J Pharm Res Allied Sci
SN  - 2277-3657
Y1  - 2026
VL  - 15
IS  - 2
DO  - 10.51847/2bOEalyk9r
SP  - 104
EP  - 113
N2  - Cell-dependent biomanufacturing has enabled diverse therapeutic products, yet its reliance on living production hosts can constrain rapid process reconfiguration, local production, and transfer across therapeutic modalities. Cell-free pharmaceutical biotechnology removes the requirement to maintain an intact production cell, but current evidence remains fragmented across reaction engineering, template design, post-translational processing, purification, stabilization, and distributed implementation. This Original Platform-Design Theory Article proposes a modular manufacturing architecture that connects a reusable cell-free production kernel with product-specific template, maturation, purification, formulation, quality, and qualification modules. The architecture distinguishes reusable infrastructure from elements that must be re-established for each product, modality, scale, or manufacturing site. Reaction-system resources are treated as interacting biochemical determinants rather than independently replaceable ingredients, while therapeutic templates are linked to folding, modification, conversion, impurity, and critical-quality-attribute requirements. Quality control is positioned as a continuous evidence layer incorporating material provenance, contamination control, recipe versioning, lot variation, analytical transfer, and intersite reproducibility. Scale transition and economic feasibility are separated from bench-scale expression because changes in extract preparation, mass transfer, resource consumption, downstream recovery, quality-system burden, and local infrastructure may alter platform performance. Proposed readiness criteria progress from conceptual specification and component functionality to integrated reproducibility, cross-lot and cross-site transfer, scale feasibility, and product-specific translational evidence. The original contribution is a conditional architecture for determining when modular substitution may be plausible and when requalification is required. It is not a validated manufacturing standard, predictive model, regulatory pathway, clinical recommendation, or deployment-ready system. Its utility requires prospective testing across therapeutic modalities, production configurations, sites, scales, and intended-use conditions. 
UR  - https://ijpras.com/article/cell-free-pharmaceutical-biotechnology-as-a-modular-manufacturing-architecture-for-rapid-distribute-ir883ssudleb9hc
ER  -